--- title: GLP-1 report description: Phesi analysis shows more than 100 diseases are being studied using GLP-1 with potential patient benefits far beyond obesity. Download the report. --- [![New_Phesi_logo_May23](https://info.phesi.com/hs-fs/hubfs/New_Phesi_logo_May23.png?width=250&height=69&name=New_Phesi_logo_May23.png "New_Phesi_logo_May23")](https://www.phesi.com/)   ### **Global Analysis** # **The Rise of Diseases Being Studied Using GLP-1 Therapies** **September 2025 **   [Download the report](https://info.phesi.com/glp-1_report#hs_cos_wrapper_widget_1756996093950) Phesi’s new global analysis shows more than 100 diseases are being studied using GLP-1 therapies with potential for patient benefits to extend far beyond obesity, opening doors to a new era of multi-disease prevention and care.  Inside the report: - The top 20 indications where GLP-1 receptor antagonists are being studied - Phesi’s GLP-1 Digital Patient Profile constructed using contextualised real-world data - Implications for clinical development and healthcare strategies    ![GLP-1_cover](https://info.phesi.com/hs-fs/hubfs/GLP-1_cover.png?width=300&height=427&name=GLP-1_cover.png "GLP-1_cover") ### Download your copy of the GLP-1 report © Phesi Inc. 2025 [mailto:e.casey@phesi.com](mailto:e.casey@phesi.com)